However, a randomized, double-blind, placebo-controlled study led by our group showed that an APE1 endonuclease inhibitor combined with docetaxel and cisplatin failed to improve the overall survival (OS) of advanced non-small cell lung cancer patients exhibiting high expression of APE1 compared to chemotherapy alone, indicating there are still unknown resistant mechanisms [14]. This evidence concerns the gene APEX1 and non-small cell lung carcinoma.